PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

travoprost Side Effects

The reactions most often reported to the FDA for travoprost (also sold as Travatan Z), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

8,423
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of travoprost come from 8,423 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 8,423 reports to the FDA Adverse Event Reporting System (FAERS) for travoprost (Travatan Z): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

8,423

Reports Mentioning Death

323

3.8% of reports — not proof the medicine caused the death

Hospitalizations

1,103

13.1% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

TREATMENT FAILURE
1,945
OCULAR HYPERAEMIA
490
EYE IRRITATION
478
EYE PAIN
336
INTRAOCULAR PRESSURE INCREASED
295
HYPERSENSITIVITY
269
FATIGUE
261
GLAUCOMA
255
VISION BLURRED
227
DIZZINESS
226
HEADACHE
226
VISUAL IMPAIRMENT
215
DEATH
204
DYSPNOEA
197
FALL
186
DIARRHOEA
182
NAUSEA
181
MALAISE
178

Who Reports Side Effects

Gender Distribution

Female 4,822 (61%)
Male 3,052 (39%)
Unknown 28

Age Distribution

0-17 24 (1%)
18-44 47 (2%)
45-64 574 (20%)
65-74 888 (32%)
75+ 1,283 (46%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 323 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 203
ASTHENIA 15
FALL 15
DYSPNOEA 14
PNEUMONIA 14
FATIGUE 13
ANAEMIA 12
DIARRHOEA 11
MYOCARDIAL INFARCTION 11
CARDIAC FAILURE CONGESTIVE 9
DEHYDRATION 9
HYPOTENSION 9
URINARY TRACT INFECTION 8
CARDIAC FAILURE 7
CONFUSIONAL STATE 7
CONSTIPATION 7
DIZZINESS 7
RENAL FAILURE 7
BACK PAIN 6

Reactions in Hospitalization Reports

Top reactions in 1,103 reports where hospitalization was an outcome.

Reaction Reports
FALL 100
FATIGUE 76
PNEUMONIA 75
DIARRHOEA 65
ACUTE KIDNEY INJURY 63
PYREXIA 63
DIZZINESS 62
DEHYDRATION 61
NAUSEA 59
DYSPNOEA 58
HEADACHE 58
ASTHENIA 55
URINARY TRACT INFECTION 51
MALAISE 49
VOMITING 45
ANAEMIA 43
CONSTIPATION 42
HAEMOGLOBIN DECREASED 39
CONFUSIONAL STATE 38
PAIN 38

Compare travoprost vs aflibercept →

What the FAERS Data Reveals About travoprost Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 8,423 voluntary reports linked to travoprost and its brand equivalents (Travatan Z), spanning 2004 through 2025. Of those, 323 (3.8%) listed death as an outcome and 1,103 (13.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 61% were female and 39% male; age distribution skews toward 75+, with 1,283 reports in that bracket. The single most reported reaction is treatment failure with 1,945 submissions, followed by ocular hyperaemia and eye irritation.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.